Sort   by:  
 Page size 
ProteomicsIntra-patient clonal diversity in HLA class I peptide ligand presentation
Tumor heterogeneity results from clonal diversity and evolutionary selection, and is a major cause of therapeutic resistance. Immunotherapy may exploit alternative vulnerabilities of drug resistant cells, and tumor-specific HLA peptide ligands on the cell surface are promising leads to invoke such t...
ORGANISM(S): Homo sapiens (Human) 
2020-10-26 | PXD016582 | Pride
Hla class i peptide ligands  colorectal cancer  tumor heterogeneity  patient-derived organoids  mass spectrometry  affinity proteomics 
Proteomics14-3-3 immunoprecipitation followed by LC-MS in MCF7 cells treated CV2a (PROTAC)
Proteins lacking defined ligandable pockets remain challenging drug targets. Here, we develop a molecular glue-based PROTAC (MGPROTACs) approach that chemically conjugates a molecular glue stabilizer to a VHL-recruiting ligand to capture and ubiquitinate the 14-3-3/Estrogen Receptor α (ERα) complex....
ORGANISM(S): Homo sapiens (Human) 
2026-07-08 | PXD075638 | Pride
14-3-3 Lc-ms Immunoprecipitation Protac 
Sort   by:  
 Page size